Create a free QxMD account to take advantage of the features offered by Read like saving your papers and creating collections.

Get Started

JOURNAL ARTICLE

The genesis of Zelboraf: targeting mutant B-Raf in melanoma

Matthew J Davis, Joseph Schlessinger

Journal of Cell Biology 2012 October 1, 199 (1): 15-9

The protein kinase B-Raf is a critical component of the Ras/MAPK signaling pathway. An oncogenic B-Raf mutation that constitutively activates the kinase was identified in ~50% of melanoma patients and in other cancers. A structure-guided drug discovery approach enabled the development of Zelboraf, a targeted inhibitor of oncogenic B-Raf. This drug has been used successfully in the clinic to treat metastatic melanoma patients harboring B-Raf mutations.

Full Text Links

Find Full Text Links for this Article

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

[Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge]. Mathieu Capovilla Annales de Pathologie 2013, 33 (6): 375-85

Oncogenic RAF: a brief history of time. David Solit, Neal Rosen Pigment Cell & Melanoma Research 2010, 23 (6): 760-2

Cutaneous manifestations of vemurafenib therapy for metastatic melanoma. Joshua L Owen, Isha E Lopez, Seemal R Desai Journal of Drugs in Dermatology: JDD 2015, 14 (5): 509-10

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Gideon Bollag, Peter Hirth, James Tsai, Jiazhong Zhang, Prabha N Ibrahim, Hanna Cho, Wayne Spevak, Chao Zhang, Ying Zhang, Gaston Habets, Elizabeth A Burton, Bernice Wong, Garson Tsang, Brian L West, Ben Powell, Rafe Shellooe, Adhirai Marimuthu, Hoa Nguyen, Kam Y J Zhang, Dean R Artis, Joseph Schlessinger, Fei Su, Brian Higgins, Raman Iyer, Kurt D'Andrea, Astrid Koehler, Michael Stumm, Paul S Lin, Richard J Lee, Joseph Grippo, Igor Puzanov, Kevin B Kim, Antoni Ribas, Grant A McArthur, Jeffrey A Sosman, Paul B Chapman, Keith T Flaherty, Xiaowei Xu, Katherine L Nathanson, Keith Nolop Nature 2010 September 30, 467 (7315): 596-9

PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma. Keiran S M Smalley Current Opinion in Investigational Drugs 2010, 11 (6): 699-706

The natural history of malignancies under conditions of BRAF inhibitor stimulation. Robert M White Expert Opinion on Investigational Drugs 2011, 20 (1): 135-6

Progression of RAS-mutant leukemia during RAF inhibitor treatment. Margaret K Callahan, Raajit Rampal, James J Harding, Virginia M Klimek, Young Rock Chung, Taha Merghoub, Jedd D Wolchok, David B Solit, Neal Rosen, Omar Abdel-Wahab, Ross L Levine, Paul B Chapman New England Journal of Medicine 2012 December 13, 367 (24): 2316-21

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Cory M Johannessen, Jesse S Boehm, So Young Kim, Sapana R Thomas, Leslie Wardwell, Laura A Johnson, Caroline M Emery, Nicolas Stransky, Alexandria P Cogdill, Jordi Barretina, Giordano Caponigro, Haley Hieronymus, Ryan R Murray, Kourosh Salehi-Ashtiani, David E Hill, Marc Vidal, Jean J Zhao, Xiaoping Yang, Ozan Alkan, Sungjoon Kim, Jennifer L Harris, Christopher J Wilson, Vic E Myer, Peter M Finan, David E Root, Thomas M Roberts, Todd Golub, Keith T Flaherty, Reinhard Dummer, Barbara L Weber, William R Sellers, Robert Schlegel, Jennifer A Wargo, William C Hahn, Levi A Garraway Nature 2010 December 16, 468 (7326): 968-72

Vemurafenib. Keith T Flaherty, Uma Yasothan, Peter Kirkpatrick Nature Reviews. Drug Discovery 2011 October 31, 10 (11): 811-2

Vemurafenib in melanoma. Heather M Shaw, Paul D Nathan Expert Review of Anticancer Therapy 2013, 13 (5): 513-22

Make the most of Read.
Download the mobile app.

Want full text access to this paper?

Use Read by QxMD to access full text via your institution or open access sources.

Read also provides personalized recommendations to keep you up to date in your field.

Existing User

New to Read

The genesis of Zelboraf: targeting mutant B-Raf in melanoma

Discussion

Related Papers

Want full text access to this paper?

Save your favorite articles in one place with a free QxMD account.

Read

Search Tips